LONG TERM DRUG SURVIVAL FOR BIOSIMILAR SB4 ETANERCEPT IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS PATIENTS WITH A NON-MEDICAL SWITCH FROM ETANERCEPT REFERENCE DRUG

被引：0
|
作者：
Haugeberg, Glenn [1 ]
Fevang, Bjorg Tilde Svanes [2 ]
Bakland, Gunnstein [3 ]
Rodevand, Erik [4 ]
Diamantopoulos, Andreas [5 ]
机构：
[1] Sorlandet Hosp Kristiansand, Rheumatol, Kristiansand, Norway
[2] Haukeland Hosp, Rheumatol, Bergen, Norway
[3] Univ Hosp North Norway HF, Rheumatol, Tromso, Norway
[4] St Olavs Hosp HF, Rheumatol, Trondheim, Norway
[5] Martina Hansens Hosp, Rheumatol, Baerum, Norway
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.7387
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0094
引用
收藏
页码：710 / 711
页数：2
相关论文
共 50 条
  • [1] COMPARING DRUG SURVIVAL FOR BIOSIMILAR SB4 ETANERCEPT IN RHEUMATOID ARTHRITIS BOTH ETANERCEPT NAIVE AND NON-MEDICAL SWITCH PATIENTS WITH ETANERCEPT REFERENCE DRUG IN A NORWEGIAN OUT-PATIENT CLINIC. PRELIMINARY RESULTS FROM A MULTI-CENTER STUDY
    Haugeberg, Glenn
    Fevang, Bjorg Tilde Svanes
    Bakland, Gunnstein
    Rodevand, Erik
    Diamantopoulos, Andreas
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1144 - 1145
  • [2] LONG-TERM SAFETY AND EFFICACY OF SB4 (ETANERCEPT BIOSIMILAR) IN PATIENTS WITH RHEUMATOID ARTHRITIS: COMPARISON BETWEEN CONTINUING SB4 AND SWITCHING FROM ETANERCEPT REFERENCE PRODUCT TO SB4
    Emery, P.
    Vencovsky, J.
    Sylwestrzak, A.
    Leszczynski, P.
    Porawska, W.
    Stasiuk, B.
    Hilt, J.
    Mosterova, Z.
    Cheong, S. Y.
    Ghil, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 236 - 236
  • [3] Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
    Emery, Paul
    Vencovsky, Jiri
    Sylwestrzak, Anna
    Leszczynski, Piotr
    Porawska, Wieslawa
    Stasiuk, Barbara
    Hilt, Joanna
    Mosterova, Zdenka
    Cheong, Yeon
    Ghil, Jeehoon
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (12) : 1986 - 1991
  • [4] Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis
    Young Hee Rho
    Anna Rychlewska-Hańczewska
    Beata Śliwowska
    Tae Hyung Kim
    [J]. Advances in Therapy, 2019, 36 : 2287 - 2295
  • [5] Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis
    Rho, Young Hee
    Rychlewska-Hanczewska, Anna
    Sliwowska, Beata
    Kim, Tae Hyung
    [J]. ADVANCES IN THERAPY, 2019, 36 (09) : 2287 - 2295
  • [6] BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis
    Selmi, C.
    Krueger, K.
    Cantagrel, A.
    Abad Hernandez, M. A.
    Freudensprung, U.
    Rezk, M. Farouk
    Addison, J.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (02) : 365 - 371
  • [7] Comparative Effectiveness and Persistence of SB4 and Reference Etanercept in Patients With Psoriatic Arthritis in Norway
    Losinska, Katarzyna
    Pripp, Are Hugo
    Bakland, Gunnstein
    Fevang, Bjorg-Tilde Svanes
    Brekke, Lene Kristin
    Wierod, Ada
    Korkosz, Mariusz
    Haugeberg, Glenn
    [J]. ARTHRITIS CARE & RESEARCH, 2024, 76 (09) : 1303 - 1312
  • [8] Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study
    Girolomoni, G.
    Feldman, S. R.
    Emery, P.
    Ghil, J.
    Keum, J. W.
    Cheong, S. Y.
    Hong, E.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (03) : E215 - E216
  • [9] DRUG SURVIVAL AND REASON FOR DROP-OUT IN RHEUMATOID ARTHRITIS PATIENTS WITH A NON-MEDICAL SWITCH FROM ORIGINATOR TO BIOSIMILAR ETANERCEPT - PRELIMINARY DATA FROM A NORWEGIAN MULTICENTER STUDY
    Haugeberg, G.
    Bakland, G.
    Rodevand, E.
    Fevang, B. T.
    Hansen, I. J. W.
    Diamantopoulos, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1383 - 1383
  • [10] OUTCOMES AFTER SWITCHING FROM ETANERCEPT ORIGINATOR TO ITS BIOSIMILAR (SB4) FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Rokad, Aasiyah
    Kearsley-Fleet, Lianne
    Watson, Kath
    Lunt, Mark
    Hyrich, Kimme L.
    [J]. RHEUMATOLOGY, 2022, 61 : I7 - U568
12345